A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma

BACKGROUND: This study evaluates a novel bronchodilator, S1226, for its efficacy in reversing allergen-induced bronchoconstriction in subjects with mild, allergic asthma. S1226 is a new class of bronchodilator that is an aerosol/vapor/gas mixture combining pharmacological and biophysical principles...

Descripción completa

Detalles Bibliográficos
Autores principales: Swystun, Veronica, Green, Francis H. Y., Dennis, John H., Rampakakis, Emmanouil, Lalli, Gurkeet, Fadayomi, Morenike, Chiu, Andrea, Shrestha, Grishma, El Shahat, Sharif Galal, Nelson, David Evan, El Mays, Tamer Y., Pieron, Cora A., Leigh, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006836/
https://www.ncbi.nlm.nih.gov/pubmed/29914544
http://dx.doi.org/10.1186/s13063-018-2720-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006836/
https://www.ncbi.nlm.nih.gov/pubmed/29914544
http://dx.doi.org/10.1186/s13063-018-2720-6

Ejemplares similares